Stifel Nicolaus Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $4.00

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective dropped by equities researchers at Stifel Nicolaus from $5.00 to $4.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock opened at $0.28 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a fifty day moving average of $0.60 and a 200-day moving average of $0.76. The stock has a market capitalization of $46.73 million, a price-to-earnings ratio of 3.47 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $3.43 million for the quarter. Equities research analysts expect that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $126,854.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at approximately $581,742.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 580,800 shares of company stock worth $321,447 in the last ninety days. 1.62% of the stock is owned by company insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of large investors have recently modified their holdings of XFOR. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals in the third quarter worth about $340,000. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals during the 3rd quarter valued at about $37,000. AQR Capital Management LLC boosted its stake in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after acquiring an additional 388,115 shares in the last quarter. K2 Principal Fund L.P. purchased a new stake in X4 Pharmaceuticals in the second quarter worth about $284,000. Finally, Ensign Peak Advisors Inc boosted its position in shares of X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.